1. Home
  2. FTK vs LBRX Comparison

FTK vs LBRX Comparison

Compare FTK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flotek Industries Inc.

FTK

Flotek Industries Inc.

HOLD

Current Price

$24.11

Market Cap

720.7M

Sector

Industrials

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$29.54

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTK
LBRX
Founded
1985
2015
Country
United States
United States
Employees
N/A
27
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
720.7M
850.5M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
FTK
LBRX
Price
$24.11
$29.54
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$20.00
$46.60
AVG Volume (30 Days)
323.4K
131.9K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
147.06
N/A
EPS
0.12
N/A
Revenue
$136,092,000.00
N/A
Revenue This Year
$13.33
N/A
Revenue Next Year
$16.38
N/A
P/E Ratio
$196.25
N/A
Revenue Growth
214.53
N/A
52 Week Low
$10.96
$13.40
52 Week High
$25.54
$33.47

Technical Indicators

Market Signals
Indicator
FTK
LBRX
Relative Strength Index (RSI) 69.72 56.04
Support Level $15.01 $26.44
Resistance Level N/A $33.47
Average True Range (ATR) 1.54 1.52
MACD 0.29 0.13
Stochastic Oscillator 76.71 89.63

Price Performance

Historical Comparison
FTK
LBRX

About FTK Flotek Industries Inc.

Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: